Clinical Trials Browser

Phase 1/2 × Recruiting × Pemetrexed × Clear all

NCT07020221 2026-04-22

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Phase 1/2 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05789082 2026-04-20

KRAScendo 170

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06741644 2026-04-15

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT04665206 2026-04-02

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasmThoracic

Mesothelioma

NCT06996782 2026-03-30

ALTAIR

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07397338 2026-03-30

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Phase 1/2 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05098132 2026-03-18

SYNERGY-101

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04165070 2026-03-16

MK-3475-01A

Phase 1/2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05410145 2026-03-12

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

Phase 1/2 Recruiting

KRAS P.G12C

NCT06162221 2026-03-09

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06772623 2026-02-27

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06405230 2026-02-03

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06462092 2025-09-29

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms, Meningeal Carcinomatosis

NCT04956640 2025-09-25

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Phase 1/2 Recruiting

GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07070440 2025-08-29

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05315700 2025-08-05

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Phase 1/2 Recruiting

Breast Neoplasms

NCT06943820 2025-06-03

AK129 Combination Therapy for Advanced Solid Tumors

Phase 1/2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06762080 2025-05-20

Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis

Phase 1/2 Recruiting

Meningeal Carcinomatosis

NCT06809517 2025-05-20

Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis

Phase 1/2 Recruiting

Meningeal Carcinomatosis

NCT06809530 2025-05-18

Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

Phase 1/2 Recruiting

Meningeal Carcinomatosis

NCT05431270 2025-01-31

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06758557 2025-01-23

A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor

Phase 1/2 Recruiting

Endometrial Neoplasms

NCT05501665 2024-10-17

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms